SyntekaBio, Inc.

A226330

KR7226330009

Software

End-of-day quote Korea S.E. Other stock markets 23:00:00 12/05/2024 BST			5-day change	1st Jan Change
9,640 ^KRW	-4.27%		-3.98%	-32.30%

05-07	Syntekabio Announces to Showcase Biologics Discovery Platform At PEGS Boston	CI
04-26	SyntekaBio, Inc. announced that it has received KRW 10 billion in funding from Korea Investment Partners Co. Ltd.	CI

SyntekaBio, Inc. announced that it has received KRW 10 billion in funding from Korea Investment Partners Co. Ltd.

April 25, 2024

On April 26, 2024, SyntekaBio, Inc. closed the transaction.

Latest news about SyntekaBio, Inc.

Syntekabio Announces to Showcase Biologics Discovery Platform At PEGS Boston	05-07	CI
SyntekaBio, Inc. announced that it has received KRW 10 billion in funding from Korea Investment Partners Co. Ltd.	04-25	CI
Syntekabio to Showcase Innovative AI Drug Discovery Technologies at Bio-IT World	04-11	CI
SyntekaBio, Inc. announced that it expects to receive KRW 10 billion in funding from Korea Investment Partners Co. Ltd.	03-27	CI
Polarisqb and Syntekabio Sign MOU for Collaborative AI and Quantum-Pored Drug Development Service	31/08/23	CI
SyntekaBio, Inc. announced that it has received KRW 10 billion in funding	27/07/23	CI
SyntekaBio, Inc. announced that it expects to receive KRW 10 billion in funding	20/07/23	CI
Syntekabio Announces the Launch of its Cost-Effective AI-Based Total Solution Service for Finding New Drug Candidates	03/06/23	CI
SyntekaBio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23/03/23	CI
Syntekabio, Inc. Launches STB Cloud Worldwide	15/12/22	CI
SyntekaBio, Inc. announced that it has received KRW 25 billion in funding from Shinhan Financial Investment Co., Ltd., Saneun Capital Co., Ltd., Best Investment & Securities Co., Ltd., IBK Capital Corporation,KDB Capital Corp., Shinhan Investment Corp., Investment Arm and other investors	29/11/21	CI
SyntekaBio, Inc. announced that it expects to receive KRW 25 billion in funding from Shinhan Financial Investment Co., Ltd., Saneun Capital Co., Ltd., Best Investment & Securities Co., Ltd., IBK Capital Corporation, KDB Capital Corp., Shinhan Investment Corp., Investment Arm and other investors	24/11/21	CI
SyntekaBio, Inc.(KOSDAQ:A226330) added to S&P Global BMI Index	21/09/20	CI
Syntekabio Presents Nonclinical Data of Immuno-Oncologic Agent Stb-C017 At the 2020 AACR Meeting	15/05/20	CI
SyntekaBio, Inc. has completed an IPO in the amount of KRW 19.2 billion.	12/12/19	CI
Syntekabio Enters into Agreement with CHA Hospital	05/12/19	CI
SyntekaBio, Inc. has filed an IPO.	26/08/19	CI
Syntekabio, Inc. announced that it has received KRW 19.69994646 billion in funding from a group of investors	20/06/19	CI
SyntekaBio, Inc. announced that it expects to receive KRW 19.69994646 billion in funding from a group of investors	04/06/19	CI
Syntekabio, Inc. announced that it has received $11.2 million in funding from Altos Ventures, Smilegate Investment, Inc., YOZMA GROUP KOREA Co.,Ltd., Korea Development Bank, Investment Arm, Korea Fixed-Income Investment Advisory	06/05/18	CI
Yuhan Enters into Agreement with Syntekabio	10/04/18	CI
Syntekabio, Inc. announced that it has received $5.6 million in funding	30/12/16	CI

Syntekabio,Inc. is a Korea-based company principally engaged in the provision of database and software. The Company develops and sells software such as personal algorithm dielectric map platform (PMAP) using artificial intelligence (AI) technology, provides clinical trial modeling and genome analysis services through big data. The analysis results are used to diagnose genetic diseases, select biomarker treatments and predict disease risk. In addition, the Company develops AI drug development technology, provides research services for candidate substances of immuno-cancer drugs.

Sector

Software

Calendar

12/05/2024 - Q1 2024 Earnings Release (Projected)

More about the company